Insilico Medicine Taiwan Limited
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Insilico’s flagship suite includes PandaOmics (multi-omics target identification), Chemistry42 (de novo molecular design), and InClinico (clinical outcome prediction). By leveraging these AI modules, they can rapidly generate novel molecules, predict safe
The content above was translated by Ai
Founded Year
2018
Unified Business No.
50759371
Status
Closed
Number of Employees
0
Total capital
29,825,137 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Insilico Medicine is a global, AI‑driven biotech company focused on generative AI for drug discovery. With headquarters in the U.S. and research facilities in Hong Kong, Taiwan, and Europe, their mission is to revolutionize drug development using their proprietary Pharma.AI platform across biology, chemistry, and clinical stages.
The content above was translated by Ai
